Pharmaceutical Product Testing
Method Development and Validation
Maxxam offers comprehensive method development and validation services for regulatory and non-regulatory investigational studies. Our validation protocols follow industry standards such as the ICH, USP or the FDA’s Guidance on Bio-analytical Methods Validation as required. We also customize our protocols to accommodate client’s individual needs and expectations.
Our customers rely on Maxxam to provide a variety of analytical testing services to identify, qualify and report product- and process-related impurities. These services include: Active Pharmaceutical Ingredients (APIs), Raw Materials testing, Clearance and Control of additives.
Our analytical experience includes work with such diverse products as peptides, metallo-drugs, medical devices, nutraceuticals, excipients and packaging materials. Pharmaceutical tests on these products includes: Heavy metals (USP <232> and <233>), Residual solvents (USP <467>), Residual catalysts (ICP-MS), and Stability & Dissolution Testing.
Additional Biologics and Biopharmaceutical testing services include:
- Process Impurities & Additives
- Silicones and antifoams (Final Bulk Product)
- Tungsten (Glass Syringes)
- GLP Extractables/Leachables studies (Design & Implementation)
Facility and Equipment
Maxxam offers a comprehensive suite of services based on advanced mass spectrometry as well as a number of supplementary liquid and gas chromatography detection methods including:
- Inductively Coupled Optical Emission Spectroscopy (ICP-OES)
- Inductively Coupled Plasma Mass Spectroscopy (ICP-MS & LC-ICP-MS)
- Gas Chromatography (MS, ECD, FID, Headspace, SPME)
- Liquid Chromatography (MS, MS/MS, UV, RI, FSA, Conductivity, Amperometry)
Our GxP laboratory facility incorporates many state of the art features including:
- Back-up generator
- Secure and fireproof data archives
- Remote monitored security access
- Remote temperature monitored & alarmed Freezers and Refrigerators
For more information please review the Pharma and Biotech section or email us: pharma@maxxam.ca.